)
Visual
test
Assembly Biosciences
Assembly Biosciences (ASMB) investor relations material
Assembly Biosciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Mar, 2026
Executive summary
Licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead after positive Phase 1b data, receiving a $35 million option fee.
Initiated process to find a partner for ABI-4334 after Gilead declined its option.
Cash position at year-end 2025 was $248.1 million, projected to fund operations into 2028.
Financial highlights
Revenue from collaborative research was $72.3 million for 2025, up from $28.5 million in 2024, reflecting increased collaboration funding.
Research and development expenses rose to $64.8 million in 2025 from $55.9 million in 2024, mainly due to increased spending on the HPI program.
General and administrative expenses increased to $19.6 million in 2025 from $18.0 million in 2024, driven by higher professional fees and stock-based compensation.
Net loss attributable to common stockholders was $6.1 million ($0.55 per share) in 2025, a significant improvement from $40.2 million ($6.69 per share) in 2024.
Outlook and guidance
Decision on whether to opt in to a 40% U.S. cost-profit share for the herpesvirus HPI program expected by mid-2026, pending Gilead's development plan.
Phase 2 clinical study for ABI-6250 in chronic hepatitis delta virus anticipated by end of 2026.
Factors for the HPI cost-profit share decision
Update on the ABI-4334 HBV partnering process
ABI-6250 HDV Phase 1a data and Phase 2 start
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Assembly Biosciences
- Biotech firm launches $100M at-the-market stock offering to fund antiviral pipeline and operations.ASMB
Registration filing19 Mar 2026 - Shelf registration allows up to $250M in securities to fund antiviral R&D and operations.ASMBRegistration Filing16 Dec 2025
- Gilead is reselling 6.98M shares, with no proceeds to the issuer, amid deep R&D collaboration.ASMBRegistration Filing16 Dec 2025
- Up to 98% HSV-2 shedding reduction and strong safety seen in Phase 1b for two novel therapies.ASMBStudy Result9 Dec 2025
- Shareholders will vote on director elections, compensation, auditor, and equity plan amendments.ASMBProxy Filing2 Dec 2025
- Director elections, compensation, plan amendments, and auditor ratification up for vote.ASMBProxy Filing2 Dec 2025
- Major clinical readouts in HBV, hepatitis delta, and herpes expected within six months.ASMBJefferies Global Healthcare Conference 202521 Nov 2025
- Potent once-weekly herpes therapies show >90% efficacy, with pivotal trials and Gilead partnership ahead.ASMBGuggenheim Securities 2nd Annual Healthcare Innovation Conference17 Nov 2025
- Strong clinical progress and Gilead partnership drive pipeline for viral disease therapies.ASMBCorporate Presentation14 Nov 2025
Next Assembly Biosciences earnings date
Q1 20266 May, 2026
Assembly Biosciences
Next Assembly Biosciences earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage